Evidence map›Paper›PMID 29062946›Full record

ReviewSynthetic and systems biotechnology2016

Recent development on synthetic biological devices treating bladder cancer.

Zhicong Chen, Anbang He, Yuchen Liu, Weiren Huang, Zhiming Cai

Abstract readReview
In one paragraph

Review in Synthetic and systems biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Synthetic biology in China, UK and US.Synthetic and systems biotechnology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhicong ChenKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518039 Guangdong Province, People's Republic of China.
Anbang HeKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518039 Guangdong Province, People's Republic of China.
Yuchen LiuKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518039 Guangdong Province, People's Republic of China.
Weiren HuangKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518039 Guangdong Province, People's Republic of China.
Zhiming CaiKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518039 Guangdong Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synthetic biology is an emerging field focusing on engineering genetic devices and biomolecular systems for a variety of applications from basic biology to biotechnology and medicine. Thanks to the tremendous advances in genomics and the chemical synthesis of DNA in the past decade, scientists are now able to engineer genetic devices and circuits for cancer research and intervention, which offer promising therapeutic strategies for cancer treatment. In this article, we provide a systemic review on recent development achieved by the synthetic biologists, oncologists and clinicians of one National "973" Plan. We expand the synthetic biology toolkits involving DNA, RNA and protein bio-parts to explore various issues in cancer research, such as elucidation of mechanisms and pathways, creation of new diagnostic tools and invention of novel therapeutic approaches. We claimed that the Chinese synthetic biologists are promoting the basic research productions of tumor synthetic biology into the clinic.

Indexed as

BiomarkerBladder cancerGene therapySynthetic biology

Identifiers

PMID29062946
PMCPMC5625735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.